创模生物科技(北京)有限公司

CN / En

NEWS

InnoModels Biotechnology: iHuPDX Platform Feature Presentation

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-06-18 15:50
  • Views:

(Summary description)With its unique iHuPDX platform, InnoModels Biotechnology has opened a whole new chapter in tumor research and clinical applications. The platform builds highly individualized disease models based on individual patient's tumor cells, which not only helps to understand the patient's tumor characteristics more comprehensively, but also provides strong support for precision medicine and the development of personalized treatment plans. In this article, we will introduce the main features of the iHuPDX platform of InnoModels Biotechnology in detail.

InnoModels Biotechnology: iHuPDX Platform Feature Presentation

(Summary description)With its unique iHuPDX platform, InnoModels Biotechnology has opened a whole new chapter in tumor research and clinical applications. The platform builds highly individualized disease models based on individual patient's tumor cells, which not only helps to understand the patient's tumor characteristics more comprehensively, but also provides strong support for precision medicine and the development of personalized treatment plans. In this article, we will introduce the main features of the iHuPDX platform of InnoModels Biotechnology in detail.

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-06-18 15:50
  • Views:
Information

With its unique iHuPDX platform, InnoModels Biotechnology has opened a whole new chapter in tumor research and clinical applications. The platform builds highly individualized disease models based on individual patient's tumor cells, which not only helps to understand the patient's tumor characteristics more comprehensively, but also provides strong support for precision medicine and the development of personalized treatment plans. In this article, we will introduce the main features of the iHuPDX platform of InnoModels Biotechnology in detail.
Firstly, the iHuPDX platform stands out for its excellent stability and growth rate. With the help of primary cell inoculation technology, the platform successfully creates an unparalleled pharmacodynamic model. This model is characterized by its cell suspension modeling approach, which ensures homogenization of samples between batches. This means that samples from the same batch maintain a high degree of consistency in growth rate and biological characteristics, thus laying a solid foundation for model stability. At the same time, homogenized samples from the same batch also ensure the stability in the same generation and after the transmission, which enables the model to maintain consistent growth and efficacy characteristics in long-term studies, providing a strong guarantee for the reliability of the experimental results.
Secondly, the iHuPDX platform realizes uniform growth at an early stage, providing an ideal experimental window for potency experiments. Efficacy experiments are usually conducted in P2-P5 generations, avoiding the problems of property changes and model wastage caused by multiple passages. In addition, the group residual can be reduced to 20% without compromising the quality of the experiment, thus significantly reducing the cost of the experiment. This feature makes the iHuPDX platform more attractive for drug discovery and clinical application.

 


In addition to stability and growth rate, the iHuPDX platform also has the ability to construct individualized disease models. Based on an individual patient's tumor cells, the platform is able to build highly individualized disease models. This helps researchers gain a more comprehensive understanding of a patient's tumor characteristics, including their unique genetic mutations, phenotype and biological behavior. Through comparative analysis of tumor models from different patients, researchers can reveal heterogeneous differences between tumors and provide strong support for the development of precision medicine.
In addition, the iHuPDX platform can be used for drug response prediction. Due to its highly individualized nature, the platform is able to simulate the response of a specific patient's tumor to a drug. This allows researchers to screen and evaluate multiple drugs in the lab to find the most effective treatment option for a specific patient. This ability to predict drug response is important for improving treatment success, reducing unwanted side effects, and lowering healthcare costs.
Finally, it is worth mentioning that the iHuPDX platform can also be combined with a humanized model of the PBMC immune system to provide ideal experimental conditions for tumor immunity research. By combining the tumor model with the immune system model, researchers can explore the interactions between tumors and the immune system in greater depth, providing important clues for the development of more effective immunotherapy strategies.
In summary, the iHuPDX platform of InnoModels Biotechnology has shown great potential in the field of tumor research and clinical applications with its stability, growth rate, ability to construct individualized disease models, and drug response prediction. With the continuous development and improvement of this platform, it is believed that it will bring more breakthroughs and innovations in tumor treatment in the future.

Keyword:

With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
In the vast field of drug discovery and life science research, InnoModels Biotechnology (Beijing) Co., Ltd. is gradually becoming a leader in the industry with its IC50 platform. The platform not only integrates advanced detection technologies, abundant cell resources and strict quality control system, but also provides researchers with efficient and reliable experimental solutions through continuous innovation and optimization.
In the field of life sciences, every leap in technology leads to deeper research and medical advances. InnoModels Biotechnology (Beijing) Co., Ltd, with its innovative 3D organoid platform, is providing scientists with an unprecedented research tool, which greatly promotes drug research and development and the exploration of disease mechanisms
In the vast starry sky of biomedical research, InnoModels Biotechnology (Beijing) Co., Ltd. is like a bright star, illuminating the journey of oncology and tumor immunology drug development with its unique PDX in vivo efficacy model. Today, let's go into InnoModels Biotechnology to learn more about its industry-leading PDX in vivo efficacy model and explore its unlimited potential in drug discovery and development.
Previous page
1
2
42
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司